Dinamika massy tela u bol'nykh sakharnymdiabetom 2 tipa v techenie pervogo godainsulinoterapii

The aim of this study was to determine changes in weight and insulin requirements in insulin-treated type 2 diabetic patients
with normal and elevated body mass index (BMI) during the first year after initiating the insulin therapy with insulin analogues or human
insulins, respectively. Materials and methods: a total of 157 patients with insulin naive type 2 diabetes were included in the study. The patients
were divided in two groups. First group consisted of subjects [mean age 57 (45 to 73), duration of diabetes of 10 years (4 to 16)]
prescribed a long-acting basal (glargine, detemir), premixed (biphasic insulin Aspart 30, Humalog Mix 25) or short-acting (aspart, lispro)
insulin analogues. Patients from second group [mean age 59 (46 to 75), duration of diabetes for 10 years (5 to 15)] were treated with intermediate-
acting basal (Protophane, Humulin NPH), premixed (biphasic human insulin 30, Humulin M3) and regular (Actrapid,
Humulin R) human insulins. Each of these two groups was divided into three subgroups depending on the baseline body mass index
(BMI) of the patients: 18,5-24,9; 25-29 and ≥30. At the beginning of insulin therapy and 12 months later, we compared HbA1c, BMI,
waist circumference and required insulin doses in each group. Results: our study results showed that under comparable metabolic control
the risk for weight gain and increase in insulin requirement is similar in insulin-treated type 2 diabetic patients with normal and elevated
BMI. Use of insulin analogues for treatment of type 2 diabetes patients with normal and elevated BMI results in better glycaemic control,
less weight gain, smaller increase in insulin requirement and waist circumference compared to human insulins during the first year of insulin
therapy.

diabetes mellitus type 2, insulin analogues, human insulin, BMI, waist circumference

1. Анциферов М.Б. Результаты UKPDS и их значение в совершенствовании специализированной помощи больным диабетом // Сахарный диабет 1999; 4: 23-28.

2. Шамхалова М.Ш., Чугунова Л.А., Шестакова М.В. Цели и задачи инсулинотерапии при сахарном диабете типа 2: место готовых смесей инсулина // Consilium- Medicum 2003; 9: 491-494.

3. American Diabetes Association. Standards of medical care of diabetes // Diabetes Care 2005; 28 (Suppl. 1): S15-S35.

4. Anderson J.V., Kendall C.V., Jenkins D.J. Importance of weight management in type 2 diabetes: review with meta-analyses of clinical studies // J Am Coll Nutr 2003; 22: 331-339.

5. Bagg W., Plank L.D., Gamble G., et al. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes // Diabetes, Obes and Metab 2001; 3: 410-416.

6. Biesenbach G., Raml A., Alsaraji N. Weight gain and insulin requirement in type 2 diabetic patients during the first year after initiating insulin therapy dependent on baseline BMI // Diabetes, Obes Metab 2006; 8: 669-673.

7. Del Prato S. Measurement of insulin resistance in vivo // Drugs 1999; 58 (Suppl. 1): 75-82.

8. European Diabetes Policy Group: A desk-top guide to type 2 diabetes mellitus // Diabet Med. 1999; 16: 716-730.

9. Hartman I. Insulin Analogues: Impact on treatment success, satisfaction, quality of life and adherence // Clinical Medicine and Research. 2008; Vol. 6. (2): 54-67.

10. Larger E., Rufat P., Dubois-Laforgue D., Ledoux S. Insulin and weight gain: myth or reality? // Diabetes Metab. 2001; 27: 23-27.

11. Larger E. Weight gain and insulin treatment // Diabetes Metab. 2005; 31: 4851- 4856.

12. Makkimattila S., Nikkila K., Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus // Diabetologia. 1999; 42: 406-412.

13. Nathan D.M., Buse J.B., Davidson M.B. et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy // Diabetes Care. 2006; 29: 1963-1972.

14. Rigalleau V., Delafaye C., Baillet L. Composition of insulin-induced body weight gain in diabetic patients: a bio-impendance study // Diabetes Metab. 1999; 25: 321-328.

15. Russel-Jones D., Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies // Diabetes, Obes Metab. 2007; 9: 799-812.

16. Stratton I.M., Adler A.I., Neil H.A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study // BMJ. 2000; 321(7258): 405-12.

17. UK Prospective Diabetes Study Group. Intensive blood glucose control with Sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. 1998; 352: 837- 853.

18. Gadsby R. Type 2 diabetes - delivery approaches for novel thera - peutics // Advanced Drug Delivery Reviews. 2002; 54: 1165-1172.

19. Yki-Yarvinen H. Combination therapies with insulin in type 2 diabetes // Diabetes Care. 2001; 24: 758-767.